ClinicalTrials.gov record NCT07800234
Establishing a National Egyptian HLH Registry (NEHR)
Establishing a National Egyptian HLH Registry (NEHR)
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
This observational registry gathers clinical information on children diagnosed with hemophagocytic lymphohistiocytosis (HLH), up to age 18. The study will record and organize those data into a national database. Its primary outcome is to establish a nationwide map of pediatric HLH over two years.
What it is studying. Collecting and organizing clinical information on children with HLH to create a national database and a nationwide map of cases.
What the researchers hope to learn. Scientific goals: establish the National Egyptian HLH Registry (NEHR) and produce a nationwide map of pediatric HLH cases.
What this study is about
The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.
Establishing a National Egyptian HLH Registry (NEHR)
Eligibility
The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.
Inclusion criteria
- patients diagnosed with hlh
Exclusion criteria
- adults
Study description and what participation involves
The registry record has no detailed description beyond the summary above.
AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
According to the registry, participation means having your diagnosis and related information entered into the National Egyptian HLH Registry (NEHR); the record lists the primary outcome as creating a nationwide HLH map over 2 years. The ClinicalTrials.gov entry does not specify any study visits, tests, blood draws, biopsies, questionnaires, or other procedures participants would undergo. The registry record also does not provide details on what exact data are collected, how long records are kept, or other participant services.
How the study is structured. This is an observational registry study using a cohort approach. Children diagnosed with HLH have their clinical information entered into the National Egyptian HLH Registry and followed as a group to map cases; no experimental treatments are assigned.
Questions you could ask
These questions are suggestions for a conversation with the study team or your own clinician, not advice.
- This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
- The listed sites are in Egypt. Is any of them reachable for me, and does the study help with travel?
- Which of the eligibility criteria would need to be checked with tests before I could join?
More on hemophagocytic lymphohistiocytosis
Important dates
- Study start
- Mar 2, 2024
- Primary completion
- Jan 1, 2028 (estimated)
- Study completion
- Dec 1, 2028 (estimated)
- Target enrollment
- 100 participants (estimated)
- Last updated on registry
- Sep 2, 2026
- Data verified
- Oct 10, 2026
Sponsor and research team
The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.
- Lead sponsor
- Ain Shams University
- Principal investigator
- Iman Ragab, Professor
Ain Shams University
Central study contact
If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.
- Iman Ragab Prof of Pediatrics, Ain Shams University, Professor 📞 +20 1002550680 ✉ hragab68@hotmail.com
- Fatma Ebeid Professor of pediatrics, Ain Shams University, Professor 📞 +201095569596
Participating sites (2)
- Faculty of Medicine Pediatric Hematology Oncology DepartmentRecruiting
Cairo, 11566 · Egypt
- Iman Ragab Professor of Pediatrics, MD · +201095569596 · hragab68@hotmail.com
- Fatma Soliman Elsayed Ebeid Professor of Pediatrics, MD · +201095569596 · fatmaebeid@med.asu.edu.eg
- Fatma SE Ebeid, MD
- Iman Ragab, MD
- Faculty of medicine ain shams universityActive Not Recruiting
Cairo · Egypt
Terms used on this page · explanations by MedicalUpdates.ai
- Registry
- An organised collection of information about people with a particular condition, gathered over time for research. Joining a registry usually means sharing medical information, not receiving a treatment.
- Inclusion Criteria
- The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
- Exclusion Criteria
- The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.
← Back to clinical trials